AR091186A1 - Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida - Google Patents
Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamidaInfo
- Publication number
- AR091186A1 AR091186A1 ARP130101864A AR091186A1 AR 091186 A1 AR091186 A1 AR 091186A1 AR P130101864 A ARP130101864 A AR P130101864A AR 091186 A1 AR091186 A1 AR 091186A1
- Authority
- AR
- Argentina
- Prior art keywords
- solid state
- isonicotinamide
- iodo
- fluoro
- forms
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 5
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
Abstract
Formas en estado sólido de N-((S)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida, a procesos para su preparación y a sus usos médicos. Reivindicación 1: Una forma en estado sólido de N-((S)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida o sus sales farmacéuticamente aceptables. Reivindicación 5: Una forma en estado sólido A1 de acuerdo con la reivindicación 3, que tiene picos característicos por rayos X de Cu-Ka₁ a ángulos 2q correspondientes a 5,5 ± 0,2, 16,8 ± 0,2, 18,5 ± 0,2, 19,1 ± 0,2, 22,6 ± 0,2, 23,0 ± 0,2, 24,9 ± 0,2, 25,2 ± 0,2, 28,4 ± 0,2, 29,2 ± 0,2 grados. Reivindicación 11: Una forma en estado sólido B1 de acuerdo con la reivindicación 4, que tiene picos característicos por rayos X de Cu-Ka₁ en ángulos 2q correspondientes 7,0 ± 0,2, 14,0 ± 0,2, 18,3 ± 0,2, 19,0 ± 0,2, 20,6 ± 0,2, 21,2 ± 0,2, 24,2 ± 0,2, 25,1 ± 0,2, 25,4 ± 0,2, 27,9 ± 0,2 grados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653037P | 2012-05-30 | 2012-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091186A1 true AR091186A1 (es) | 2015-01-14 |
Family
ID=48537929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101864 AR091186A1 (es) | 2012-05-30 | 2013-05-29 | Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9260393B2 (es) |
| EP (1) | EP2855434B1 (es) |
| JP (1) | JP6280543B2 (es) |
| KR (1) | KR20150022923A (es) |
| CN (1) | CN104334530A (es) |
| AR (1) | AR091186A1 (es) |
| AU (1) | AU2013269994B2 (es) |
| BR (1) | BR112014029838A2 (es) |
| CA (1) | CA2875145C (es) |
| CL (1) | CL2014003285A1 (es) |
| DK (1) | DK2855434T3 (es) |
| EA (1) | EA028059B1 (es) |
| ES (1) | ES2592860T3 (es) |
| HK (1) | HK1206733A1 (es) |
| HR (1) | HRP20161135T1 (es) |
| HU (1) | HUE028850T2 (es) |
| IL (1) | IL235947A (es) |
| LT (1) | LT2855434T (es) |
| MX (1) | MX350295B (es) |
| MY (1) | MY169266A (es) |
| NZ (1) | NZ701103A (es) |
| PL (1) | PL2855434T3 (es) |
| PT (1) | PT2855434T (es) |
| RS (1) | RS55167B1 (es) |
| SG (1) | SG11201407842TA (es) |
| SI (1) | SI2855434T1 (es) |
| TW (1) | TWI570108B (es) |
| UA (1) | UA112899C2 (es) |
| WO (1) | WO2013178320A1 (es) |
| ZA (1) | ZA201409426B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| US10179132B2 (en) | 2015-05-26 | 2019-01-15 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same |
| KR20160138756A (ko) * | 2015-05-26 | 2016-12-06 | 연세대학교 산학협력단 | 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법 |
| MY194462A (en) | 2016-11-25 | 2022-11-30 | Genuv Inc | Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same |
| KR101833412B1 (ko) | 2017-07-24 | 2018-02-28 | 연세대학교 산학협력단 | 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010014360A (ko) * | 1997-07-01 | 2001-02-26 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 2-(4-브로모 또는 4-요오도 페닐아미노)벤조산 유도체 및ｍｅｋ 억제제로서의 그의 용도 |
| KR20010108093A (ko) * | 1999-01-13 | 2001-12-07 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 1-헤테로고리 치환된 디아릴아민 |
| WO2003101988A2 (en) * | 2002-05-31 | 2003-12-11 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| AR051248A1 (es) * | 2004-10-20 | 2007-01-03 | Applied Research Systems | Derivados de 3-arilamino piridina |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
-
2013
- 2013-05-07 PL PL13725913.1T patent/PL2855434T3/pl unknown
- 2013-05-07 MX MX2014014520A patent/MX350295B/es active IP Right Grant
- 2013-05-07 BR BR112014029838A patent/BR112014029838A2/pt not_active Application Discontinuation
- 2013-05-07 HU HUE13725913A patent/HUE028850T2/en unknown
- 2013-05-07 SG SG11201407842TA patent/SG11201407842TA/en unknown
- 2013-05-07 EP EP13725913.1A patent/EP2855434B1/en active Active
- 2013-05-07 CA CA2875145A patent/CA2875145C/en active Active
- 2013-05-07 ES ES13725913.1T patent/ES2592860T3/es active Active
- 2013-05-07 AU AU2013269994A patent/AU2013269994B2/en active Active
- 2013-05-07 CN CN201380028114.0A patent/CN104334530A/zh active Pending
- 2013-05-07 KR KR20147036740A patent/KR20150022923A/ko not_active Ceased
- 2013-05-07 US US14/404,060 patent/US9260393B2/en active Active
- 2013-05-07 JP JP2015514374A patent/JP6280543B2/ja active Active
- 2013-05-07 PT PT137259131T patent/PT2855434T/pt unknown
- 2013-05-07 NZ NZ701103A patent/NZ701103A/en not_active IP Right Cessation
- 2013-05-07 LT LTEP13725913.1T patent/LT2855434T/lt unknown
- 2013-05-07 DK DK13725913.1T patent/DK2855434T3/en active
- 2013-05-07 WO PCT/EP2013/001352 patent/WO2013178320A1/en active Application Filing
- 2013-05-07 SI SI201330301A patent/SI2855434T1/sl unknown
- 2013-05-07 MY MYPI2014703509A patent/MY169266A/en unknown
- 2013-05-07 EA EA201401341A patent/EA028059B1/ru not_active IP Right Cessation
- 2013-05-07 RS RS20160795A patent/RS55167B1/sr unknown
- 2013-05-29 TW TW102119003A patent/TWI570108B/zh active
- 2013-05-29 AR ARP130101864 patent/AR091186A1/es unknown
- 2013-07-05 UA UAA201413849A patent/UA112899C2/uk unknown
-
2014
- 2014-11-27 IL IL235947A patent/IL235947A/en not_active IP Right Cessation
- 2014-11-28 CL CL2014003285A patent/CL2014003285A1/es unknown
- 2014-12-19 ZA ZA2014/09426A patent/ZA201409426B/en unknown
-
2015
- 2015-07-30 HK HK15107274.5A patent/HK1206733A1/xx unknown
-
2016
- 2016-09-05 HR HRP20161135TT patent/HRP20161135T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023417A2 (pt) | compostos heterocíclicos e seus usos | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| HRP20191489T1 (hr) | Kombinirani sastav | |
| CR20150232A (es) | Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| EA201071204A1 (ru) | Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности | |
| CR20120620A (es) | Nuevas formas de rifaximina y usos de las mismas | |
| AR091186A1 (es) | Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida | |
| ECSP11011076A (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
| RS54238B1 (en) | ORAL FILM FORMULATIONS CONTAINING DAPOXETINE AND TADALAFIL | |
| BR112013014441A2 (pt) | microrganismo tendo uma melhor capacidade de produzir ornitina e método para produzir ornitina usando o mesmo | |
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| GT201200304A (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| UY34786A (es) | Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo | |
| BR112015012443A2 (pt) | composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza | |
| IL228666A0 (en) | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans | |
| CL2014002908A1 (es) | Método para la preparación de 2-(2,3-dimetilfenil)-1-propanal y sus usos. | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| CL2014003126A1 (es) | Metabolitos de (1r-trans)-n-[[2-(2,3-dihidro-4-benzofuranil) ciclopropil]metil] propanamida; composicion farmaceutica que lo contiene; y sus usos. | |
| BR112014030949A2 (pt) | "composição, processo para o tratamento cosmético e uso de uma composição" | |
| BR112014021067A2 (pt) | formas unitárias de dosagem oral e usos das mesmas para o tratamento da doença de gaucher | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| CL2015001308A1 (es) | Pastilla medicinal para chupar a base de ibuprofeno sodico dihidratado; metodo de preparación y el uso en el tratamiento de los trastornos orofaringeos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |